Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

Rare Earths Stocks: 9 Biggest Companies in 2024

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Investing in Graphene Companies (Updated 2024)

Mark These Tax-loss Selling Dates on Your Calendar (Updated 2024)

Trending Press Releases

US$30 Million Prepayment Term Sheet and Offtake Agreement Executed with a Global Commodities Trader

Radiopharm achieves Nasdaq listing of ADS

SAGA Metals Reports Channel Sample Assay Results at Double Mer Uranium Project

SAGA Metals Completes OTCQB Listing and Receives DTC Eligibility

Mount Hope Mining: Advancing a Copper, Gold-rich Asset in the Cobar Basin of New South Wales

Significant Milestone Achieved in Development Journey with The Completion of The "first phase" of the Environmental Impact Assessment Procedure for Rajapalot Gold-Cobalt Project

More Press Releases
Trending Companies

Purpose Bitcoin ETF

BTCC:CA

First Helium

HELI:CA

Soma Gold Corp.

SOMA:CA

GTI Energy

GTR:AU
More Companies
Trending Reports

2024 Gold Outlook Report

2024 Uranium Outlook

Silver Price Forecast - What Happened And Where Do We Go From Here?

Rare Earths Outlook Report

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Relay Therapeutics Inc.

NASDAQ:RLAY
Press Releases

Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Ka mutant selective program, known as the RLY-PI3K1047 program. Its initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020.

Interactive Chart

×